Athira Pharma Reports Reduced Losses Amid Cost Cuts

Athira Pharma, Inc. ( (ATHA) ) has released its Q3 earnings. Here is a breakdown of the information Athira Pharma, Inc. presented to its investors.

Athira Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, operating primarily in the biotechnology sector. In its latest earnings report, Athira Pharma revealed a significant reduction in operating expenses and a narrower net loss compared to the previous year. The company reported a net loss of $6.6 million for the third quarter of 2025, a notable improvement from the $28.7 million loss in the same period last year. This reduction in losses is attributed to a substantial decrease in research and development expenses, which fell to $2.8 million from $17.9 million, and a decrease in general and administrative expenses. Despite these improvements, Athira continues to face challenges, including the need for additional funding to support its operations and the development of its drug candidates. Looking ahead, Athira Pharma’s management remains focused on advancing its pipeline, particularly its lead candidate ATH-1105, while exploring strategic transactions to bolster its financial position.